| Literature DB >> 33567540 |
Franck Paganelli1,2, Giovanna Mottola1,3, Julien Fromonot1,3, Marion Marlinge1,3, Pierre Deharo1,4, Régis Guieu1,3, Jean Ruf1.
Abstract
The influence of hyperhomocysteinemia (HHCy) on cardiovascular disease (CVD) remains unclear. HHCy is associated with inflammation and atherosclerosis, and it is an independent risk factor for CVD, stroke and myocardial infarction. However, homocysteine (HCy)-lowering therapy does not affect the inflammatory state of CVD patients, and it has little influence on cardiovascular risk. The HCy degradation product hydrogen sulfide (H2S) is a cardioprotector. Previous research proposed a positive role of H2S in the cardiovascular system, and we discuss some recent data suggesting that HHCy worsens CVD by increasing the production of H2S, which decreases the expression of adenosine A2A receptors on the surface of immune and cardiovascular cells to cause inflammation and ischemia, respectively.Entities:
Keywords: adenosine; adenosine A2A receptors; cardiovascular disease; hydrogen sulfide; hyperhomocysteinemia
Mesh:
Substances:
Year: 2021 PMID: 33567540 PMCID: PMC7914561 DOI: 10.3390/ijms22041690
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923